COLLEEN BROPHY, MD
Radiology at 21 Ave, Nashville, TN

2012026, Oct 18, 2012

Apr 12, 2012

13/445759

Cynthia Lander - Mendham NJ, US
Colleen Brophy - Nashville TN, US

MOERAE MATRIX, INC. - HIGHLAND PARK NJ

A61K 38/17, A61P 11/00, A61K 38/21, A61K 38/39, A61K 39/395

424 855, 514 214, 514 172, 4241451, 4241581, 4241331

The described invention provides compositions and methods for preventing or treating a disease, condition, or pathologic process characterized by aberrant fibroblast proliferation and extracellular matrix deposition in a tissue of a subject. The method includes administering a therapeutic amount of a pharmaceutical composition comprising a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier.

2014007, Mar 13, 2014

Sep 10, 2013

14/022902

Susan Eagle - Nashville TN, US
Kyle Hocking - Alpharetta GA, US
Franz Baudenbacher - Franklin TN, US
Colleen Brophy - Nashville TN, US

Vanderbilt University - Nashville TN

A61M 5/172, A61B 5/0215

600490, 604 66, 604503

One aspect of the present disclosure is a system for hemodynamic resuscitation. The system includes an intravenous access device having a pressure sensor element configured to detect a peripheral venous pressure value in response to an occlusion of a peripheral vein. The system also includes a controller device that is configured to receive a signal from the pressure sensor comprising the peripheral venous pressure value, to process the signal to determine a hemodynamic parameter based on the peripheral venous pressure value, and to generate a resuscitation score based on the hemodynamic parameter.

2011028, Nov 24, 2011

May 24, 2011

13/114872

Cynthia Lander - Mendham NJ, US
Colleen Brophy - Nashville TN, US
Brandon Seal - Pleasant Grove UT, US

A61K 38/16, A61K 38/08, A61P 9/00, A61K 38/10

514 214, 514 216, 514 215, 514 217

The described invention provides pharmaceutical compositions and methods for treating or preventing vascular graft failure in a subject in need of such treatment, the method comprising administering a therapeutically effective amount of a composition comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof, and a pharmaceutically acceptable carrier. The methods also are clinically useful for treating a pre-atherosclerotic intimal hyperplasia condition.

2011019, Aug 4, 2011

Dec 8, 2010

12/963375

Colleen M. Brophy - Nashville TN, US
Padmini Komalavilas - Nashville TN, US
Joyce Cheung-Flynn - Nashville TN, US
Kyle M. Hocking - Nashville TN, US
Susan S. Eagle - Nashville TN, US

A61B 17/00, A01N 1/02

600 36, 435 11

The leading cause of graft failure is the subsequent development of intimal hyperplasia, which represents a response to injury that is thought to involve smooth muscle proliferation, migration, phenotypic modulation, and extracellular matrix (ECM) deposition. Surgical techniques typically employed for vein harvest—stretching the vein, placing the vein in low pH, solutions, and the use of toxic surgical skin markers—are shown here to cause injury. The invention therefore provides for non-toxic surgical markers than also protect against stretch-induced loss of functional viability, along with other additives. Devices and compositions for reducing physical stress or protecting from the effects flowing therefrom, also are provided.

2013011, May 9, 2013

May 24, 2011

13/700087

Cynthia Lander - Mendham, NJ
Alyssa Panitch - West Lafayette IN, US
Colleen Brophy - Nashville TN, US
Brandon Seal - Pleasant Grove UT, US

C07K 7/06, C07K 7/08

424400, 514 214, 514 213, 514 19

The described invention provides pharmaceutical compositions and methods for treating or preventing vascular graft failure in a subject in need of such treatment, the method comprising administering a therapeutically effective amount of a composition comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof, and a pharmaceutically acceptable carrier. The methods also are clinically useful for treating a pre-atherosclerotic intimal hyperplasia condition.

2010000, Jan 7, 2010

Oct 30, 2006

12/090474

Colleen Brophy - Nashville TN, US
Alyssa Panitch - W. Lafayette IN, US
Elizabeth Furnish - Tempe AZ, US
Brandon Seal - Mesa AZ, US

The Arizona Board of Regents, a body corporate acting on behalf of Arizona State University - Scottsdale AZ

A61K 38/16, C07K 7/06, C07K 7/08, C07K 14/00, A61K 38/08, A61K 38/10, C07H 21/00, C12N 15/74, C12N 1/00, A61P 35/00

514 12, 530329, 530328, 530327, 530326, 530325, 530324, 530350, 514 16, 514 15, 514 14, 536 231, 4353201, 435243

The present invention provides novel transduction domains, compositions comprising such transduction domains, and their use for in vivo molecular delivery.

2011002, Feb 3, 2011

Jul 10, 2007

12/305885

Luciana Biagini Lopes - Clifton Park NY, US
Elizabeth J. Furnish - Tempe AZ, US
Charles Robert Flynn - Chandler AZ, US
Padmini Komalavilas - Tempe AZ, US
Alyssa Panitch - W. Lafayette IN, US
Colleen M. Brophy - Nashville TN, US

The Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State Universi - Scottsdale AZ

A61K 38/16, A61P 9/04, A61P 17/02, A61P 27/02, A61K 38/10, A61P 13/12, A61P 1/16, A61P 19/04

514 154, 514 164, 514 186, 514 208, 514 215, 514 214

The present invention provides methods for treating and/or limiting fibrotic disorders and/or treating or limiting scars selected from the group consisting of keloids and hypertrophic scars comprising administering to an individual in need thereof an amount effective to treat and/or limit scars selected from the group consisting of keloids and hypertrophic scars of a polypeptide comprising an HSP20-related polypeptide.